Table 1. Patient characteristics at the time of V(D)J sequencing.
| Smoldering multiple myeloma | Newly diagnosed multiple myeloma | Relapsing/ refractory multiple myeloma | |
|---|---|---|---|
| Number of patients | 26 | 104 | 47 |
| Gender (male)* | 12 (46%) | 55 (53%) | 25 (53%) |
| Age at sampling (years)** | 63 (55.25–75) | 63 (55.75–71) | 62 (57.5–67.5) |
| PC % on BM aspirate differential** | 12% (8–19.75) | 23.5% (11.75–44) | 25% (12.5–40) |
| PC % on BM biopsy** | 13% (10–20) | 50% (20–80) | 37.5% (15–67.5) |
| Monoclonal PC as % of WBC by flow of BM** | 0.55% (0.2–2.575) | 2% (0.3–11) | 2.4% (0.4–5.6) |
| Ig heavy chain* | |||
| IgG | 20 (77%) | 61 (59%) | 28 (60%) |
| IgA | 4 (15%) | 28 (27%) | 8 (17%) |
| IgD | 0 (0%) | 2 (2%) | 0 (0%) |
| None | 2 (8%) | 13 (12%) | 11 (23%) |
| Ig light chain* | |||
| Kappa | 15 (58%) | 71 (68%) | 27 (57%) |
| Lambda | 11 (42%) | 33 (32%) | 20 (43%) |
| None | 0 (0%) | 0 (0%) | 1 (2%) |
| Serum M-spike (g/dl)** | 0.9 (0.4–1.6) | 2.2 (0.8–3.2) | 1.1 (0.2–2) |
| Involved s-FLC (mg/dl)** | 11.2 (2.8–16) | 38 (9.6–115.6) | 26.8 (3.4–94) |
| Ratio of involved to uninvolved s-FLC** | 13 (5–30) | 59 (12–214.5) | 80 (9–686) |